Five platforms. One translational pipeline.
Five platforms. One translational pipeline
Injectable Self-Gelling Wafer
A patented in-situ gelling implant for post-surgical application, designed to prevent tumor recurrence through localized, sustained drug release.
In-situ gelation
Injectable liquid forms a gel depot at body temperature.
Sustained release
Controlled therapeutic delivery over several weeks.
Localized control
Targets residual cells at the surgical resection margin.
Image-guided
Compatible with MRI/CT monitoring post-implant.
From cavity injection to sustained release
Cavity Injection
- Liquid sol, injectable viscosity
- Customizable volume
- Following tumor resection
In-Situ Gelation
- Triggered at 37°C body temp
- Solidifies in < 2 minutes
- Conformal coverage
Depot Formation
- Fills irregular margins
- High tissue adhesion
- MRI / CT visible
Sustained Release
- Zero-order release kinetics
- 4–6 week duration
- Minimal systemic toxicity
Miragen Wafer vs. Gliadel®
| Feature | Gliadel® (Standard) | Miragen Wafer |
|---|---|---|
| Administration | Surgical implant | Injectable |
| Geometry | Rigid disc | Conformal gel |
| Duration | ~2–3 weeks | Tunable (months) |
TRL 4–5 · Preclinical Validated
Validated in orthotopic mouse models showing sustained release and tumor suppression, with a scale-up protocol established.
Next milestone: toxicology studies and formulation stability work ahead of IND filing.
Target partnership: neurosurgery departments for post-operative clinical trials.
BBB-Penetrating Nanotubes
A nose-to-brain delivery system using self-assembled, transferrin-targeted nanotubes to bypass the blood-brain barrier for non-invasive glioblastoma treatment.
The blood-brain barrier excludes nearly all small-molecule drugs and 100% of large-molecule biologics, while active efflux pumps eject many therapeutic agents back into circulation — forcing the high systemic doses that cause severe side effects.
Intranasal RationaleMiragen's nanotubes travel the nose-to-brain pathway via the olfactory and trigeminal nerves — bypassing the BBB entirely, reaching the CNS within minutes, and avoiding first-pass metabolism.
Passive targeting: Through Enhanced Permeation and Retention Effect modulated by size and charge of the Nanotubes as per stage of the tumor.
Payload: Temozolomide (TMZ) with combination agents for tumor heterogeneity coverage.
In vivo evidence across two cancer models
BBB Crossing Confirmed
Ex vivo fluorescence imaging 24 hours after intranasal administration confirmed brain accumulation and co-localization with glioblastoma cells, validating BBB penetration and tumor-specific targeting.
Tumor volume: ~4.13 mm³ · Max radiance: 2.22×10⁶ p/sec/cm²/sr
Systemic Tumor Targeting
Whole-body and ex vivo imaging confirmed nanoparticle accumulation and retention specifically in breast tumor tissue respectively, validating the controlled and sustained delivery mechanism.
Suggests potential for treating breast-to-brain metastases.
Therapeutic Impact
Tumor shrinkage (growth inhibition) vs control (free drug, vehicle control), median survival analysis with organs and systemic toxicity
Model: Orthotopic GBM mouse model (brain tumor)
Model: Orthotopic brain metastasis model (breast to brain tumor targeting)
Formulation built for scale-up from day one
A Quality-by-Design approach defines Critical Process Parameters across nanoprecipitation, tangential flow filtration, and sterile filtration — currently validated at 10L per batch and GMP-ready, with release specifications including PDI < 0.2, encapsulation efficiency > 85%, and endotoxin < 0.5 EU/mL.
Transdermal Nanoparticles
A patented lipid-based delivery system engineered to overcome stratum corneum barriers for deep dermal penetration of therapeutics and micronutrients.
Oleic acid acts as a permeation enhancer, disrupting the ordered lipid packing of the stratum corneum to create fluidized channels for nanoparticle entry — achieving deep dermal penetration where standard liposomes remain on the skin surface.
Draize scale evaluation on six human volunteers confirmed zero irritation, with the lipid-based nanoparticle platform passing the full safety protocol.
Irritation potential: 0.0 / 4.0
Draize scale protocol — passed.
GRAS-approved materials
Biocompatible, biodegradable lipids throughout.
Micronutrient fortification, built for cosmetic bases
Lip Salve
Nanoparticle-infused stick for daily micronutrient delivery.
Face Packs
Multani mitti base enriched with dermal-penetrating nutrients.
Transdermal Creams
Therapeutic bases for Vitamin B12 and other active ingredients.
Microneedle Patches
A self-applicable, pain-free transdermal system for non-invasive delivery of biomolecules, vitamins, and vaccines with improved patient compliance.
Microneedles penetrate the stratum corneum without reaching nerve endings, enabling a simple press-and-apply mechanism for home use — no bio-hazardous sharps waste, with dissolving formulations available.
Pain-free application
Minimal discomfort, no needle anxiety.
Self-administration
Patient-friendly, no clinic visit required.
Custom payloads
Vitamins, micronutrients, and small molecules.
Better compliance
Bypasses GI degradation and pill fatigue.
TRL · Prototype Optimization Phase
Lab Validation
Optimization
GMP Scale-Up
Commercialization
Seeking: GMP manufacturing partners, CDSCO regulatory consultants, and precision molding partners for tech transfer.
SPR Optical Biosensor
A label-free, portable optical biosensing system for the rapid, early detection of breast and brain cancer biomarkers from a liquid biopsy.
Real-time analysis
Instantaneous binding kinetics, without fluorescent labels.
Liquid biopsy
Non-invasive detection directly from serum or plasma.
High sensitivity
Detects low-abundance autoantibodies at pg/mL concentration.
Portable point-of-care
Integrated microfluidics designed for point-of-care testing.
Physics, biology, and device — in one workflow
The physics: the sensor detects changes in refractive index at a metal-dielectric interface; binding events alter the angle of minimum reflectivity.
The biology: disease-specific antigens are immobilized on the sensor chip; patient serum is introduced to detect autoantibodies.
The device: an automated microfluidic sample-handling system is integrated with the optical sensor for under-100µL samples and sub-30-minute results.
SPR vs. current standard-of-care diagnostics
| Parameter | MRI / PET-CT | ELISA / Serology | Miragen SPR |
|---|---|---|---|
| Cost per test (India) | ₹8,000 – ₹30,000+ | ₹2,000 – ₹5,000 | Target < ₹1,000 |
| Time to result | Hours – days | 4 – 24 hours | < 30 minutes |
| Sensitivity | Requires visible tumor mass | ng/mL – µg/mL | pg/mL (ultra-sensitive) |
| Accessibility | Centralized imaging center | Laboratory required | Point-of-care, field-deployable |
Comparison based on current clinical oncology guidelines (NCCN) and Miragen internal data.
Strategic roadmap — currently in Lab Validation
Proof of Concept
- Sensor fabrication
- Microfluidic design
- Initial buffer tests
Analytical Validation
- LoD / LoQ establishment
- Specificity studies
- Reproducibility tests
Clinical Validation
- Patient cohort study
- Comparison vs. standard
- Statistical analysis
Regulatory & Scale
- CDSCO device filing
- Manufacturing transfer
- Commercial pilot
What we're seeking from partners: access to patient cohorts (breast/brain), biobanking support, clinician feedback on protocol design, and blinded validation studies.